Phase 1 Insomnia Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
Mindfulness Meditation for Insomnia
InsomniaMindfulnessTelemedicine+2 more
Brigham and Women's Hospital30 enrolled1 locationNCT06972303
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fed conditions in healthy male and female volunteers.
N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000966796
Completed
Phase 1
Phase I, open label, randomised three-way cross over study to determine the safety and pharmacokinetics of CBD administered as a single oral dose to healthy volunteers
Insomnia
Bod Limited15 enrolled1 locationACTRN12622000961741
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteers.
N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000957796
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fasting conditions in healthy male and female volunteers.
N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000956707
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet against the innovator N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet conducted under fed conditions in healthy male and female volunteers.
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000126718
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet against the innovator N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet conducted under fasting conditions and at steady state in healthy male and female volunteers.
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000109707
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet against the innovator N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide prolonged release tablet conducted under fasting conditions in healthy male and female volunteers.
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000108718
Completed
Phase 1
A phase I study to measure the absorption of cannabidiol (CBD) in healthy volunteers after consumption of an oral CBD soft-gel capsule
Insomnia
Avecho Biotechnology16 enrolled1 locationACTRN12621001181897
Completed
Phase 1
A study of the safety and tolerability of single doses of wafers containing cannabidiol (CBD) that dissolve under the tongue compared to CBD oil that is swallowed in healthy volunteers.
PainInsomniaAnxiety+2 more
iX Biopharma Pty Ltd12 enrolled1 locationACTRN12620000891921
Completed
Phase 1
A trial to evaluate an oral medicinal cannabis extract compared with placebo for the treatment of insomnia.
Insomnia
Zelda Therapeutics Limited24 enrolled1 locationACTRN12618000078257